AU2015298156B2 - Purification platform for bispecific antibodies - Google Patents

Purification platform for bispecific antibodies Download PDF

Info

Publication number
AU2015298156B2
AU2015298156B2 AU2015298156A AU2015298156A AU2015298156B2 AU 2015298156 B2 AU2015298156 B2 AU 2015298156B2 AU 2015298156 A AU2015298156 A AU 2015298156A AU 2015298156 A AU2015298156 A AU 2015298156A AU 2015298156 B2 AU2015298156 B2 AU 2015298156B2
Authority
AU
Australia
Prior art keywords
protein
binding
buffer
affinity
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015298156A
Other languages
English (en)
Other versions
AU2015298156A1 (en
Inventor
Benjamin Adams
Hanne BAK
Christine EDICOTT
John MATTILA
Andrew TUSTIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2015298156A1 publication Critical patent/AU2015298156A1/en
Application granted granted Critical
Publication of AU2015298156B2 publication Critical patent/AU2015298156B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3819—Affinity chromatography of the nucleic acid-nucleic acid binding protein type
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/26—Cation exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2015298156A 2014-07-26 2015-07-24 Purification platform for bispecific antibodies Active AU2015298156B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462029463P 2014-07-26 2014-07-26
US62/029,463 2014-07-26
PCT/US2015/041936 WO2016018740A2 (en) 2014-07-26 2015-07-24 Purification platform for bispecific antibodies

Publications (2)

Publication Number Publication Date
AU2015298156A1 AU2015298156A1 (en) 2017-02-23
AU2015298156B2 true AU2015298156B2 (en) 2020-07-16

Family

ID=53836215

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015298156A Active AU2015298156B2 (en) 2014-07-26 2015-07-24 Purification platform for bispecific antibodies

Country Status (19)

Country Link
US (1) US10626142B2 (enExample)
EP (2) EP3172221B1 (enExample)
JP (1) JP6702967B2 (enExample)
KR (1) KR102440737B1 (enExample)
CN (1) CN107074906B (enExample)
AR (1) AR101262A1 (enExample)
AU (1) AU2015298156B2 (enExample)
DK (2) DK3172221T3 (enExample)
EA (1) EA036154B1 (enExample)
ES (2) ES2881026T3 (enExample)
FI (1) FI3912987T3 (enExample)
IL (1) IL255198B (enExample)
MX (1) MX377558B (enExample)
MY (1) MY187051A (enExample)
PL (2) PL3172221T3 (enExample)
SG (2) SG10201900661YA (enExample)
TW (1) TWI704155B (enExample)
WO (1) WO2016018740A2 (enExample)
ZA (1) ZA201700622B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
CN115925961A (zh) * 2015-05-28 2023-04-07 生物辐射实验室股份有限公司 亲和配体及其相关方法
SG11201803989WA (en) * 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
ES3055961T3 (en) 2016-04-28 2026-02-17 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
ES2874974T3 (es) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Matriz de separación
ES2909833T3 (es) 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Método de limpieza y/o desinfección de una matriz de separación
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
TWI798179B (zh) * 2016-06-17 2023-04-11 美商建南德克公司 多特異性抗體之純化
WO2018038469A1 (ko) * 2016-08-20 2018-03-01 (주)아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
KR101933656B1 (ko) 2016-08-20 2018-12-28 (주) 아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
EP3603670A4 (en) 2017-03-31 2021-03-10 Public University Corporation Nara Medical University MEDICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BLOOD CLOG FACTOR IX ANOMALY WITH A MULTI-SPECIFIC ANTIGIBINDING MOLECULAR FUNCTION OF BLOOD CLOTHING FACTOR VIII
TW202600611A (zh) 2017-11-01 2026-01-01 日商中外製藥股份有限公司 生物活性降低之抗體變異體與同功型
WO2019183334A1 (en) 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
GB201805142D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Bioprocess R&D Ab Separation method
US12152056B2 (en) * 2018-08-17 2024-11-26 Regeneron Pharmaceuticals, Inc. Method and chromatography system for determining amount and purity of a multimeric protein
AU2019343053B2 (en) * 2018-09-21 2026-04-30 Teneobio, Inc. Methods for purifying heterodimeric, multispecific antibodies
WO2020066270A1 (ja) * 2018-09-28 2020-04-02 株式会社カネカ κ鎖可変領域を含む抗体および／または抗体断片の製造方法
AU2019369421A1 (en) 2018-10-31 2021-06-03 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying a protein
MX2021005863A (es) * 2018-11-21 2021-07-16 Regeneron Pharma Anticuerpos antiestafilococo y usos de estos.
US20220009959A1 (en) * 2018-11-26 2022-01-13 North Carolina State University Peptide ligands for capture of host cell proteins
US11249089B2 (en) 2018-12-12 2022-02-15 Regeneron Pharmaceuticals, Inc. System and method of analysis of a protein using liquid chromatography-mass spectrometry
MA54601A (fr) 2018-12-24 2022-03-30 Sanofi Sa Nouvelles protéines de liaison multi-spécifiques à base de pseudofab
EP3934620A1 (en) 2019-03-05 2022-01-12 Regeneron Pharmaceuticals, Inc. Human serum albumin in formulations
BR112021023335A2 (pt) 2019-06-11 2022-01-04 Regeneron Pharma Anticorpos recombinante isolado ou seu fragmento de ligação ao antígeno e monoclonal isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, método de diminuição do risco de adquirir infecção por p. aeruginosa, e, métodos de diminuição da carga bacteriana em um sujeito com uma infecção por p. aeruginosa, de aumento da sobrevida ou da probabilidade de sobrevida de um sujeito que sofre de infecção por p. aeruginosa ou de um sujeito que corre risco de infecção por p. aeruginosa, para melhorar ou reduzir a gravidade, a duração ou a frequência de ocorrência de pelo menos um sintoma de uma infecção por p. aeruginosa, para aumentar a sobrevida ou a probabilidade de sobrevida de um sujeito que sofre de fibrose cística
JP7653920B2 (ja) * 2019-06-13 2025-03-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多段階クロマトグラフィープロセス中の望ましくない成分を除去する方法
KR20240007293A (ko) 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
EP4141025A4 (en) * 2019-12-26 2024-04-24 ABL Bio, Inc. Method for purifying biologically active peptide by using protein a affinity chromatography
KR102834449B1 (ko) 2019-12-27 2025-07-15 케이에스광학주식회사 투명한 방탄 적층 구조물
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
WO2022158889A1 (en) * 2021-01-25 2022-07-28 Yuhan Corporation Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody
GB202109246D0 (en) * 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies
CN115960241B (zh) * 2021-10-12 2026-05-05 苏州生物医药转化工程中心 一种针对表皮生长因子受体双特异性抗体的Protein A纯化保存方法
WO2023068740A1 (ko) * 2021-10-19 2023-04-27 주식회사 알테오젠 Igg fc 도메인을 가지는 융합 단백질의 정제방법
KR20250028362A (ko) * 2022-06-22 2025-02-28 씨티바 바이오프로세스 알＆디 에이비 카파 경쇄-결합 대류 매트릭스
US20250076310A1 (en) 2022-12-08 2025-03-06 Regeneron Pharmaceuticals, Inc. Methods to characterizing a fragment crystallizable domain of a bispecific antibody
CN116769044A (zh) * 2023-07-11 2023-09-19 康日百奥生物科技(苏州)有限公司 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法
WO2025073922A1 (en) * 2023-10-04 2025-04-10 Sartorius Bia Separations D.O.O. Enhanced chromatographic separations of components in a mixture by employing chaotropic elution
TW202540433A (zh) 2023-11-21 2025-10-16 美商再生元醫藥公司 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化
WO2025131519A1 (en) * 2023-12-21 2025-06-26 Cytiva Bioprocess R&D Ab Antibody separation with a vh3 binding separation matrix
WO2025173342A1 (ja) * 2024-02-13 2025-08-21 Jsr株式会社 Ｆｃ融合タンパク質を精製するためのクロマトグラフィー用担体、及びそれを用いたＦｃ融合タンパク質の精製方法
WO2026075981A1 (en) * 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Methods of analyzing heterodimeric proteins

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO2010151792A1 (en) * 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2012123520A1 (en) * 2011-03-17 2012-09-20 Chromacon Ag Method for identification and purification of multi-specific polypeptides
WO2013136186A2 (en) * 2012-03-13 2013-09-19 Novimmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
WO2014049003A1 (en) * 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
US20140112914A1 (en) * 2010-11-30 2014-04-24 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626413D0 (en) 1986-11-05 1986-12-03 Gilliland L K Antibodies
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
ATE210682T1 (de) 1996-09-03 2001-12-15 Gsf Forschungszentrum Umwelt Zerstörung von kontaminierenden tumorzellen in stammzelltransplantaten mit bispezifischen antikörpern
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
ES2212638T3 (es) 1998-09-25 2004-07-16 Lindhofer, Horst, Dr. Utilizacion de celulas tumorales en tiempo escalonado en combinacion con anticuerpos intactos para la inmunizacion.
US7169903B2 (en) 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US20030224000A1 (en) 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
BRPI0611600B8 (pt) * 2005-06-17 2021-05-25 Wyeth Corp método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
CL2008000883A1 (es) * 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
SG149759A1 (en) * 2007-07-10 2009-02-27 Millipore Corp Media for affinity chromatography
US20110166332A1 (en) * 2008-09-12 2011-07-07 Ge Healthcare Bio-Sciences Ab Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2522724B1 (en) * 2009-12-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Polypeptide modification method for purifying polypeptide multimers
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO2010151792A1 (en) * 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
US20140112914A1 (en) * 2010-11-30 2014-04-24 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
WO2012123520A1 (en) * 2011-03-17 2012-09-20 Chromacon Ag Method for identification and purification of multi-specific polypeptides
WO2013136186A2 (en) * 2012-03-13 2013-09-19 Novimmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
WO2014049003A1 (en) * 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins

Also Published As

Publication number Publication date
MY187051A (en) 2021-08-27
FI3912987T3 (fi) 2023-06-19
DK3912987T3 (da) 2023-05-01
WO2016018740A8 (en) 2021-06-10
JP2017524740A (ja) 2017-08-31
EP3172221B1 (en) 2021-07-07
ZA201700622B (en) 2020-05-27
TWI704155B (zh) 2020-09-11
NZ728700A (en) 2023-09-29
EA201790247A1 (ru) 2017-08-31
PL3172221T3 (pl) 2021-12-27
DK3172221T3 (da) 2021-08-09
US20160024147A1 (en) 2016-01-28
CN107074906A (zh) 2017-08-18
WO2016018740A3 (en) 2016-03-17
KR20170035941A (ko) 2017-03-31
AR101262A1 (es) 2016-12-07
CA2955618A1 (en) 2016-02-04
MX377558B (es) 2025-03-10
SG11201700157VA (en) 2017-02-27
ES2942533T3 (es) 2023-06-02
ES2881026T3 (es) 2021-11-26
EP3912987B1 (en) 2023-03-22
CN107074906B (zh) 2021-05-14
AU2015298156A1 (en) 2017-02-23
IL255198A0 (en) 2017-12-31
IL255198B (en) 2022-04-01
EP3172221A2 (en) 2017-05-31
BR112017001443A2 (pt) 2017-12-05
JP6702967B2 (ja) 2020-06-03
EP3912987A1 (en) 2021-11-24
EP3912987B9 (en) 2023-05-31
TW201617359A (zh) 2016-05-16
EA036154B1 (ru) 2020-10-06
WO2016018740A2 (en) 2016-02-04
PL3912987T3 (pl) 2023-07-24
US10626142B2 (en) 2020-04-21
KR102440737B1 (ko) 2022-09-06
MX2017001217A (es) 2017-05-03
SG10201900661YA (en) 2019-02-27

Similar Documents

Publication Publication Date Title
EP3912987B9 (en) Purification platform for bispecific antibodies
US12545702B2 (en) Methods for removing undesired components during multistage chromatographic processes
CA2955618C (en) Purification platform for bispecific antibodies
HK40062836B (en) Purification platform for bispecific antibodies
HK40062836A (en) Purification platform for bispecific antibodies
US20260132168A1 (en) Methods for Removing Undesired Components During Multistage Chromatographic Processes
US20230242579A1 (en) Methods for Improving Resolution of Heterodimeric Proteins from Impurities Using Affinity Chromatography
HK1234069B (en) Purification platform for bispecific antibodies
US20260092928A1 (en) Methods of analyzing heterodimeric ¿proteins
NZ728700B2 (en) Purification platform for bispecific antibodies
BR112017001443B1 (pt) Método para fabricação de uma proteína
EA045004B1 (ru) Способы удаления нежелательных компонентов в многостадийных хроматографических процессах
EA049572B1 (ru) Способы удаления нежелательных компонентов в многостадийных хроматографических процессах
EA049692B1 (ru) Способы для улучшения отделения гетеродимерных белков от примесей с применением аффинной хроматографии
AU2017347809A1 (en) Purification process for removal of tyrosine sulfation antibody variants; purified compositions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)